Headquartered in Beijing, China, CapitalBio is a leading life science Company that develops and commercializes total health-care solutions including a broad range of innovative biochip-related products for genomic, proteomic and cellomic research, bio-safety testing, clinical applications and to address wider human health needs. CapitalBio warmly encourages discussion of new business, marketing and production opportunities, etc. Both through innovation and a commitment to rapid product development, CapitalBio is seeking to reduce the cost of products, to benefit our customers.
CapitalBio's range of microarray-based biochips include the diagnostic chips for numerous diseases and infections, food safety test chips for antibiotics and food-borne pathogens in farm animals, and poultry, and a variety of DNA based whole genome arrays for gene expression profiling and genotyping to elucidate the gene functions in man, animals, plants and lower organisms. Our innovative Human Leukocyte Antigen (HLA) genome typing chip and technology have set new standards for high throughput and accurate HLA typing.
Innovation drives CapitalBio's continued growth in the Life Science technology field. CapitalBio also develops various cutting-edge biochips utilizing microfluidic technology, microprocessor technology and bio-electro-magnetic technology. These include a self-contained fully integrated micrometrix device, an electro-rotational field measuring chip for cell viability test, a bioelectronic chip with cell positioning electrodes and signal measuring electrodes for neuron cell network monitoring, and a gas chromatography microchip, for various applications. The company's state-of-the-art confocal Laser Microarray Scanner, LuxScan™ 10K and AlphaScan™ have been marketed by some of the most well-known names in the field and adopted by customers around the globe, including numerous clinical laboratories in Asia, Europe, America and the Middle East.
CapitalBio has two fully owned subsidaries: CaptialBio International based in San Diego, California and CapitalBio Hong Kong, China.
CapitalBio has also created two affiliated companies by the early transfer of IP.
AVIVA Biosciences, a San Diego, California based company that develops and markets on-chip patch-clamp technologies for ion-channel studies for drug discovery research.
Chipscreen Biosciences, a Biotech company located in Shenzhen, China, for small molecular drug discovery and development.